IPO-Note Tarsons Products Limited
Rs 635 – Rs 662 per Equity share Recommendation: SUBSCRIBE

Company Profile: –

Tarsons Products Ltd. is an Indian company engaged in the designing, development, manufacturing and marketing of diverse range of quality labware products including benchtop equipment, used in across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations , Diagnostic companies and hospital manufactures a range of quality labware products that helps advance scientific discovery. The company had a diversified product portfolio with over 1,700 SKUs across 300 products. Its product portfolio is classified into three key categories. Some of its end customers include customers such as Indian Institute of Chemical Technology, National Centre, Dr Reddy’s Laboratories, Metropolis Healthcare, Dr Lal Path Labs, TPL distributes products to these end customers on a Pan-India basis through authorized distributors. The company has long-standing relationships with end customers as well as distributors. The company currently operates through five manufacturing facilities located in West Bengal. These facilities are vertically integrated and equipped with automated support systems that help the company in maintaining quality, increasing productivity, and reducing costs.

Tarsons Products Ltd IPO – Details

                                                                                      Issue Details
Objects of the issue  ·Repayment/ Prepayment of borrowing of the company;

·Funding a part of capital expenditure for new manufacturing facility, and

·General corporate Purpose. 

Issue Size Total issue Size -Rs. 1023.84 Cr.

Offer for Sale – Rs. 150 Cr.

Fresh Issue –Rs. 873.84 Cr.

Face value Rs.2.00 Per Equity Share
Issue Price Rs. 635 – Rs. 662
Bid Lot 22 shares
Listing at  BSE, NSE
Issue Opens: 15th Nov, 2021 – 17th Nov, 2021
QIB 50% of Net Issue Offer
Retail 35% of Net Issue Offer
NIB 15% of Net Issue Offer

Tarsons Product Ltd IPO

Wants To Apply Online

Trade AnyTime AnyWhere With Elite Empower Mobile App


Check Tarsons Product Ltd IPO Allotment Status

Tarsons Product Ltd  IPO allotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.

One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-

  1. To Tarsons Product Ltd  IPO Allotment Status
  2. Go to Application Status
  3. Select IPO as Tarsons Product Ltd IPO
  4. Enter your PAN Number or Application Id or DP Client Id.


Tarsons Product Ltd IPO

Application Form

Tarsons Products Ltd IPO Financial Performance:


Tarsons Products Ltd IPO Shareholding Pattern:

Shareholding Pattern Pre- Issue Post Issue
Promoters & Promoter Group 50.75% 42.03%
Public  49.25% 57.97%
Source: RHP, EWL Research

Tarsons Products Ltd IPO Strengths:

  • Strong Distribution network of over 140 Authorised Distributor and worldwide presence in 40 countries.

  • Leading supplier of life sciences products and have good product offering

  • Well-equipped and automated manufacturing facilities with Strong sales and distribution network

Tarsons Products Ltd IPO Key Highlights:

  • Revenue from operations has grown at a CAGR of 12.62% from FY19-21

  • EBITDA Margin improved from 42.03% in FY19 to 46.45% in FY21

  • PAT has grown at a CAGR of 33% from FY 19-21, in FY 21 Company Profit has improved from 38.99 cr in FY 19 to 68.87 cr.

  • ROCE of the company improved from 31.61% in FY 19 to 34.54%.

  • Exports to 40 countries through 45 authorized distributors which make up 25-30% of their total revenue.

  • On consolidated basis company reported cash flow of ₹ 68cr in FY 21.

Tarsons Products IPO Risk Factors:

  • Delay or interruption in imports (which make up 75% of raw materials)

  • Geographical & Political risks of having plants only in West Bengal.

  • High Competition & Fragmented Industry, Maintenance of quality is must.


Tarsons Products has more than three decades of experience in the science labware and plastic labware industry. They are leader in production and supply of laboratory plastic ware for use within molecular biology, cell culture, genomics, proteomics and immunology in India. The product vast product range, with sound knowledge and expertise in plastic moulding, they also provide customized products as per the laboratory needs. Tarsons supply their products to healthcare, pharmaceutical, biotech, food and environment sectors globally. The business model is supported by stable and recurring revenues, significant operating leverage that can come from expansion Plan Company generate healthy cash flow. At the higher price band of Rs 197, the offer is made at P/E multiple of 51.15x of FY21 EPS, considering the uniqueness of business and  the growth ahead for the company, we recommend SUBSCRIBE rating to the IPO.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

Need An Assistance:

    Product Interested